Generation of a concise gene panel for outcome prediction in urinary bladder cancer. - Wikidata - wikimedia - TriplyDB

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

http://www.wikidata.org/entity/Q33561596

about

Molecular substratification of bladder cancer: moving towards individualized patient management Emerging critical role of molecular testing in diagnostic genitourinary pathology EZH2 in Bladder Cancer, a Promising Therapeutic Target Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.Re: Joseph Chin. In Search of the Perfect Crystal Ball for Ta Urothelial Cancer. Eur Urol. doi:10.1016/j.eururo.2009.09.014.Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer.Expression profiling for bladder cancer: strategies to uncover prognostic factors.Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer Modelling bladder cancer in mice: opportunities and challenges.Three differentiation states risk-stratify bladder cancer into distinct subtypes Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Development of prognostic signatures for intermediate-risk papillary thyroid cancer Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma.Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract.Diagnosis and management of urothelial carcinoma of the bladder.Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales?Neoadjuvant chemotherapy for invasive bladder cancer.Novel molecular targets for the therapy of urothelial carcinoma.Prognostic value of cell-cycle regulation biomarkers in bladder cancer.Emerging personalized approaches for the management of advanced urothelial carcinoma.Molecular markers in bladder cancer: Novel research frontiers.The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145.S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells.Roles of Signal Transducer Pathways in Investigation of Biopsies from Patients with Bladder Tumors Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy.Indications for postoperative radiotherapy in laryngeal carcinoma: a panel of tumor tissue markers for predicting locoregional recurrence in surgically treated carcinoma. A pilot study.Impact of risk factors on functional status in maintenance hemodialysis patients.Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer.Prediction of recurrence of non muscle-invasive bladder cancer by means of a protein signature identified by antibody microarray analyses.Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.

P2860

Q26744343-640BB496-3B24-4689-AB2C-5D101E97589C Q27021371-5CCF27CF-9A8E-4F83-BE31-69B896A7EE05 Q28082054-811CCB44-AF6E-4729-B6FE-8544CB0A7182 Q28477345-311C0F29-0D54-4733-AD00-BF99DB4F5C8E Q33618520-05DA9652-BC79-487A-9036-25B901DF0C79 Q33687900-FF8DF987-451A-4349-944F-0C9942435A1A Q34202435-D9AFD420-1C75-4AE5-891C-F82BC11B4D54 Q34537170-21CC127E-B0C1-4A3A-9E07-A073D01B707F Q34563208-8A37AED3-DC7C-498B-AA19-EF089C207364 Q35285703-DEA42702-9FCD-4A4E-A3D1-E60E1E7F8A9E Q35750975-A6D2A5A4-0D8B-4C9A-B58F-EF81901ED4E3 Q36061127-248FA6E4-01B3-40E1-AB55-553F768287A8 Q36134855-003F4B28-539F-4C0E-BB53-BB8B5CC8CFC6 Q36589325-D5974395-7174-4956-A25F-ADABADF8836F Q36600567-E2A5F4AA-12C3-4D0E-B87B-0AF50C55E25E Q37209662-1017E45E-CA65-481E-9C6D-C6A3B967F509 Q37385267-935CB9D9-F1AA-480D-96A0-9CE08BF0F0D0 Q37630359-A39BB475-8CE8-46F2-8F24-A6F65B68C5A6 Q37665504-77A74F59-2546-4D52-97CB-600E409C9DA6 Q37676257-329BD6A5-71FF-443E-BFD3-54B1759E80B0 Q37681783-3E2CA843-7A5C-4C0F-85C4-BE604C9AFA89 Q37874887-9DB92117-EBEB-4019-A91B-99A2FBC2CDF8 Q37894668-324D5F21-F0E6-4EDF-9961-C3171BAC49D4 Q37982318-85319A0A-6DC7-4501-98E2-FCA09471CDAE Q38003195-A372F4E9-E203-47DA-825C-5A67AA7CD04F Q38049692-8528302E-BD9D-4F7B-ACA7-D086FC685676 Q38068583-74C838EF-60DD-498B-A3CC-A7EE00DCAA68 Q38520403-9F24C74B-731A-4D55-B3EA-1C7171B1DFCB Q38618562-8BA79875-0FE6-464E-BE22-888AB4A5A177 Q38715437-E942C37A-85D3-4893-AF34-3A0A79D3D742 Q39015239-7BC300EE-DE38-4986-87D9-55CAAC9EF861 Q39024758-700A896D-01F5-4F06-AB6A-4D9E1D37DCBE Q41461442-0BBCC83C-91A7-4CE7-A043-7F38233672B2 Q42275760-41F3FF23-7BDE-4ECE-8F03-6D1579CD4CCE Q44841435-5DF1B616-7A16-4C16-B16A-0FE58E1384A2 Q45353605-F92734A6-3998-4706-8E08-6659263E2FA6 Q47215582-C0C55B52-A948-4EF4-9F2E-D5263E84E0EF Q52672946-004132A4-2B2B-449C-B9B1-3A8851DD9BC2 Q53063306-8C28009B-F510-43C8-85EE-A5EA533AFF80 Q54242629-E6443828-8F19-49F7-A882-88B65615D893

P2860

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

http://www.wikidata.org/entity/Q33561596

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@ast

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@en

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@nl

type

label

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@ast

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@en

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@nl

prefLabel

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@ast

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@en

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@nl

P1433

Q33561596-5420ED8D-91CD-4EEC-A198-5D51177E4E06

P1476

Q33561596-F317EA9F-6FD6-4E1B-ACA7-9134FDA350A0

P2093

Q33561596-0287E9D7-0C0D-457A-8F94-A526110A3754

Q33561596-38046F10-EAD0-403D-90C5-E64161E357C9

Q33561596-672DD4EF-49F4-4F4F-B67B-1A4D167E0F82

Q33561596-77357C04-1110-4267-96F7-DF3F82ABBC4F

Q33561596-B1F079F5-7CC7-4E39-8FF8-4A2F98BFAFB3

Q33561596-B256758B-B9B2-4665-89AE-7D77EADD8373

Q33561596-F8B4689A-807B-4813-9D84-27BAD5DCDCDE

P2860

Q33561596-04C0FF3B-4DD6-4D8D-ACF9-A3081885141C

Q33561596-0589BC36-80EB-44F7-8D6B-87CD872A6401

Q33561596-0EA1DBD2-6250-428B-8AFD-B7D08BC6C388

Q33561596-1864AFE1-5D0D-45F5-9898-48F190A3020D

Q33561596-1E9D34D8-337D-4464-B599-CFFF34F7A310

Q33561596-2DD4556D-400E-4F17-A1F8-9C9900B90EDA

Q33561596-32DC156D-5A2A-4523-9B80-35CFAA507E72

Q33561596-42908562-8570-4CEE-A20A-FBCF1A2BED09

Q33561596-4B1BF699-F5CD-4140-9942-5C7DFECF35A8

Q33561596-5C1BC95B-7245-48DF-BC71-E3268120C623

P304

Q33561596-AAD15E6F-678F-4682-85A8-F9BFD64C0D83

P31

Q33561596-B1A8A81C-53EB-49AA-8632-19E5C96DFB52

P356

Q33561596-68AB4FC9-6CA7-4344-94A0-9604CA5AE620

P407

Q33561596-C2CB6510-8DE4-4B7B-8444-DDD07B09D78A

P433

Q33561596-F4F360A1-79C7-4401-BBFC-8A0CEDD88CFA

P478

Q33561596-38285741-CD14-4277-9965-71DC4DF67A3D

P50

Q33561596-2C6E91FC-52C3-4F77-BB27-66470B5CA116

P577

Q33561596-7A27ED2A-61A0-41FB-B5FD-888DA86FA7D4

P5875

Q33561596-24CEE16F-B33A-4009-ABE0-2AC069988F78

P698

Q33561596-D0D9CFC1-EBF7-4F55-9856-D91EC7BC7C3F

P932

Q33561596-7A551D07-0736-46C4-8C58-089FC5CAFA23

P356

JCO.2008.18.5744

P1433

Journal of Clinical Oncology

P1476

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

@en

P2093

Anirban P Mitra

http://www.w3.org/2001/XMLSchema#string

Donald G Skinner

http://www.w3.org/2001/XMLSchema#string

Frederic M Waldman

http://www.w3.org/2001/XMLSchema#string

Ram H Datar

http://www.w3.org/2001/XMLSchema#string

Richard J Cote

http://www.w3.org/2001/XMLSchema#string

Susan Groshen

http://www.w3.org/2001/XMLSchema#string

Vincenzo Pagliarulo

http://www.w3.org/2001/XMLSchema#string

P2860

Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR

Analysis of matched mRNA measurements from two different microarray technologies.

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Early detection of lung cancer: role of biomarkers.

Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses.

Molecular staging of bladder cancer.

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR.

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

P304

3929-3937

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.5744

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26684175

http://www.w3.org/2001/XMLSchema#string

P698

19620494

http://www.w3.org/2001/XMLSchema#string

P932

2799152

http://www.w3.org/2001/XMLSchema#string